Ethan Troy-Barnes, Melat Rone, Madeleine Daly, Lia Estrada, Sharron Ramirez, Lubna Awas, Chris Steward, Sofhia Akhtar, Zeynab Jeewa, Patrick O'Brien, Sam Alimam
{"title":"当代患者血液管理异常侵入性胎盘在三级中心,重点是输血从业者的作用。","authors":"Ethan Troy-Barnes, Melat Rone, Madeleine Daly, Lia Estrada, Sharron Ramirez, Lubna Awas, Chris Steward, Sofhia Akhtar, Zeynab Jeewa, Patrick O'Brien, Sam Alimam","doi":"10.1111/vox.70063","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Abnormally invasive placenta (AIP) refers to a rare (<0.2% of live births) spectrum of obstetric disorders characterized by dysfunctional placental implantation, associated with major obstetric haemorrhage at delivery. There is limited evidence regarding effective patient blood management (PBM) strategies peripartum. In this study, we describe the clinical characteristics and outcomes of AIP at our centre over a 5-year period, with a particular focus on PBM.</p><p><strong>Materials and methods: </strong>We carried out a retrospective review of the electronic medical records for all (34) women with AIP who underwent delivery between January 2019 and November 2023.</p><p><strong>Results: </strong>At delivery, the median age was 37 years (range 25-52) and the median gestational age was 36 weeks (range 29-39). All deliveries were by caesarean section and coordinated through a multidisciplinary approach with direct input from a transfusion practitioner (TP) during delivery. The median estimated blood loss was 4.7 L (range 0.7-14). Thirty-two (94%) patients received packed red blood cells (median 6 units, range 0-23). Red cell salvage (RCS) was performed in 29 (85%). There were no maternal or neonatal deaths. Seventeen (50%) patients underwent hysterectomy and 17 (50%) required intensive therapy unit admission. There was no maternal red cell alloimmunization or acute transfusion reactions.</p><p><strong>Conclusion: </strong>Our data reinforce the importance of effective PBM strategies for AIP by demonstrating favourable survival outcomes with a hysterectomy rate of 50% using a multidisciplinary approach with direct involvement by a TP and utilizing RCS.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"913-920"},"PeriodicalIF":1.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Contemporary patient blood management in abnormally invasive placenta at a tertiary centre, with a focus on the role of the transfusion practitioner.\",\"authors\":\"Ethan Troy-Barnes, Melat Rone, Madeleine Daly, Lia Estrada, Sharron Ramirez, Lubna Awas, Chris Steward, Sofhia Akhtar, Zeynab Jeewa, Patrick O'Brien, Sam Alimam\",\"doi\":\"10.1111/vox.70063\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>Abnormally invasive placenta (AIP) refers to a rare (<0.2% of live births) spectrum of obstetric disorders characterized by dysfunctional placental implantation, associated with major obstetric haemorrhage at delivery. There is limited evidence regarding effective patient blood management (PBM) strategies peripartum. In this study, we describe the clinical characteristics and outcomes of AIP at our centre over a 5-year period, with a particular focus on PBM.</p><p><strong>Materials and methods: </strong>We carried out a retrospective review of the electronic medical records for all (34) women with AIP who underwent delivery between January 2019 and November 2023.</p><p><strong>Results: </strong>At delivery, the median age was 37 years (range 25-52) and the median gestational age was 36 weeks (range 29-39). All deliveries were by caesarean section and coordinated through a multidisciplinary approach with direct input from a transfusion practitioner (TP) during delivery. The median estimated blood loss was 4.7 L (range 0.7-14). Thirty-two (94%) patients received packed red blood cells (median 6 units, range 0-23). Red cell salvage (RCS) was performed in 29 (85%). There were no maternal or neonatal deaths. Seventeen (50%) patients underwent hysterectomy and 17 (50%) required intensive therapy unit admission. There was no maternal red cell alloimmunization or acute transfusion reactions.</p><p><strong>Conclusion: </strong>Our data reinforce the importance of effective PBM strategies for AIP by demonstrating favourable survival outcomes with a hysterectomy rate of 50% using a multidisciplinary approach with direct involvement by a TP and utilizing RCS.</p>\",\"PeriodicalId\":23631,\"journal\":{\"name\":\"Vox Sanguinis\",\"volume\":\" \",\"pages\":\"913-920\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vox Sanguinis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/vox.70063\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/6/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vox Sanguinis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/vox.70063","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Contemporary patient blood management in abnormally invasive placenta at a tertiary centre, with a focus on the role of the transfusion practitioner.
Background and objectives: Abnormally invasive placenta (AIP) refers to a rare (<0.2% of live births) spectrum of obstetric disorders characterized by dysfunctional placental implantation, associated with major obstetric haemorrhage at delivery. There is limited evidence regarding effective patient blood management (PBM) strategies peripartum. In this study, we describe the clinical characteristics and outcomes of AIP at our centre over a 5-year period, with a particular focus on PBM.
Materials and methods: We carried out a retrospective review of the electronic medical records for all (34) women with AIP who underwent delivery between January 2019 and November 2023.
Results: At delivery, the median age was 37 years (range 25-52) and the median gestational age was 36 weeks (range 29-39). All deliveries were by caesarean section and coordinated through a multidisciplinary approach with direct input from a transfusion practitioner (TP) during delivery. The median estimated blood loss was 4.7 L (range 0.7-14). Thirty-two (94%) patients received packed red blood cells (median 6 units, range 0-23). Red cell salvage (RCS) was performed in 29 (85%). There were no maternal or neonatal deaths. Seventeen (50%) patients underwent hysterectomy and 17 (50%) required intensive therapy unit admission. There was no maternal red cell alloimmunization or acute transfusion reactions.
Conclusion: Our data reinforce the importance of effective PBM strategies for AIP by demonstrating favourable survival outcomes with a hysterectomy rate of 50% using a multidisciplinary approach with direct involvement by a TP and utilizing RCS.
期刊介绍:
Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections:
1) Transfusion - Transmitted Disease and its Prevention:
Identification and epidemiology of infectious agents transmissible by blood;
Bacterial contamination of blood components;
Donor recruitment and selection methods;
Pathogen inactivation.
2) Blood Component Collection and Production:
Blood collection methods and devices (including apheresis);
Plasma fractionation techniques and plasma derivatives;
Preparation of labile blood components;
Inventory management;
Hematopoietic progenitor cell collection and storage;
Collection and storage of tissues;
Quality management and good manufacturing practice;
Automation and information technology.
3) Transfusion Medicine and New Therapies:
Transfusion thresholds and audits;
Haemovigilance;
Clinical trials regarding appropriate haemotherapy;
Non-infectious adverse affects of transfusion;
Therapeutic apheresis;
Support of transplant patients;
Gene therapy and immunotherapy.
4) Immunohaematology and Immunogenetics:
Autoimmunity in haematology;
Alloimmunity of blood;
Pre-transfusion testing;
Immunodiagnostics;
Immunobiology;
Complement in immunohaematology;
Blood typing reagents;
Genetic markers of blood cells and serum proteins: polymorphisms and function;
Genetic markers and disease;
Parentage testing and forensic immunohaematology.
5) Cellular Therapy:
Cell-based therapies;
Stem cell sources;
Stem cell processing and storage;
Stem cell products;
Stem cell plasticity;
Regenerative medicine with cells;
Cellular immunotherapy;
Molecular therapy;
Gene therapy.